Detalhe da pesquisa
1.
Safety of AS04-HPV-16/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18-25 years: A 10-year follow-up study.
Asia Pac J Clin Oncol
; 19(4): 458-467, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36101936
2.
Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial.
Hum Vaccin Immunother
; 17(4): 955-964, 2021 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33180670
3.
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Cancer Med
; 8(14): 6195-6211, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31305011
4.
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.
Cancer Med
; 6(1): 12-25, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27998015